Evolution of age-related breast cancer and postmenopausal breast cancer remains a major challenge, with increasing elements showing the role of pre-inflammatory cytokines and CXC chemoinochane in tumor development and immune system configuration. As the global population ages, the understanding of the complex connections between aging, inflammation and the development of cancer is becoming increasingly critical.
The aging process is accompanied by changes in the microenval of the tumor, including enhancing extracellular uterine and the accumulation of inflammatory immunists, such as interleukin (IL-6, IL-8), the tumor necrosis factor (TNF) (CXCL1, CXCL9, CXCL110, CXCL11111111111, CXCL1111, CXCL1111, CXCL111, CXCL111, CXCL CXCL12). These factors contribute to the development of tumor, metastasis and avoidance of the immune system, especially in postmenopausal women.
Obesity induced by chronic inflammation further enhances the dangers, as excessive adipose tissue leads to overproduction of cytokines and adipokines. This inflammatory environment enhances the aggression of the tumor, affects the infiltration of immunocytes and modifies hormone signaling, thereby increasing the sensitivity of breast cancer in postmenopausal women. Studies have shown that increased levels of CXCL8/IL-8 and CXCL12/CXCR4 are associated with tumor evolution, making these basic goals for possible therapeutic interventions.
A critical aspect of the development of age -related breast cancer is immune system dysfunction, especially the decrease in tils lymphocyte and reduced response to the inhibitors of the immune control point. The secretive secretion -related secretion (SASP), characterized by the release of inflammatory cytokines, plays a central role in this process, contributing to the development of tumor and the suppression of the immune system. The effects on the volume of IL-6, IL-1B and CXCLS emphasize the importance of inflammation driven by cytocin as a therapeutic strategy.
Advances in interventions focusing on the formation of cytokines and chemocine maintain the promise of improved breast cancer treatment in older women. Treating the interaction between aging, obesity, inflammation and immunological function, the researchers aim to develop personalized treatments that mitigate the evolution of the tumor while maintaining the maintenance of immunological monitoring.
With the increasing incidence of postmenopausal breast cancer, the need for innovative approaches aimed at inflammatory streets has never been more pressing. By spreading complex molecular mechanisms that form the basis of age -related cancer, the scientific community paves the way for more effective and customized treatment strategies that can significantly improve the effects of patients.
Source:
Magazine report:
Ullah, a., et al. (2025). The management and postmenopausal evolution of breast cancer and treatment management: the importance of pre-inflammatory cytokines and CXC chemochane. Genes and diseases. doi.org/10.1016/j.gendis.2025.101606.
